The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo
- 17 February 2009
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (7) , 2325-2330
Abstract
C-Src kinase is a rate-limiting activator of osteoclast (OC) function and Src inhibitors are therefore candidate antiosteoporosis drugs. By affecting αvβ3 and macrophage-colony stimulating factor (M-CSF)-induced signaling, c-Src is central to osteoclast activity, but not differentiation. We find Lyn, another member of Src family kinases (SFK) is, in contrast, a negative regulator of osteoclastic bone resorption. The absence of Lyn enhances receptor activator of NF-κB ligand (RANKL)-mediated differentiation of osteoclast precursors without affecting proliferation and survival, while its overexpression decreases osteoclast formation. In further contrast to c-Src, Lyn deficiency does not impact the activity of the mature cell. Reflecting increased osteoclast development in vitro, Lyn−/− mice undergo accelerated osteoclastogenesis and bone loss, in vivo, in response to RANKL. Mechanistically, Lyn forms a complex with receptor activator of NF-κB (RANK), the tyrosine phosphatase, SHP-1, and the adapter protein, Grb2-associated binder 2 (Gab2). Upon RANKL exposure, Gab2 phosphorylation, JNK, and NF-κB activation are enhanced in Lyn−/− osteoclasts, all critical events in osteoclast development. We therefore establish that Lyn regulates osteoclast formation and does it in a manner antithetical to that of c-Src. The most pragmatic aspect of our findings is that successful therapeutic inhibition of c-Src, in the context of the osteoclast, will require its stringent targeting.Keywords
This publication has 48 references indexed in Scilit:
- RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in miceJournal of Clinical Investigation, 2008
- RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiationProceedings of the National Academy of Sciences, 2008
- Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorptionJournal of Cell Biology, 2007
- PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2Journal of Clinical Investigation, 2006
- Glucocorticoids suppress bone formation via the osteoclastJournal of Clinical Investigation, 2006
- FHL2 inhibits the activated osteoclast in a TRAF6-dependent mannerJournal of Clinical Investigation, 2005
- The Inositol 5′-Phosphatase SHIP-1 and the Src Kinase Lyn Negatively Regulate Macrophage Colony-stimulating Factor-induced Akt ActivityJournal of Biological Chemistry, 2003
- The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me/me mutant miceBone, 1999
- Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1Oncogene, 1999
- Osteoclasts express high levels of pp60c-src in association with intracellular membranes.Journal of Cell Biology, 1992